Health Care & Life Sciences » Pharmaceuticals | Catalyst Biosciences Inc.

Catalyst Biosciences Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
92,329.00
107,385.00
66,292.00
36,532.00
37,776.00
120,177
Total Accounts Receivable
278.00
141.00
492.00
31.00
24.00
-
Other Current Assets
999.00
615.00
1,914.00
958.00
1,309.00
3,814
Total Current Assets
93,606.00
108,141.00
68,698.00
37,521.00
39,109.00
123,991
Net Property, Plant & Equipment
682.00
428.00
698.00
444.00
276.00
386
Total Investments and Advances
51,448.00
3,418.00
125.00
125.00
-
-
Intangible Assets
97.00
-
-
-
-
-
Other Assets
40.00
12.00
-
-
128.00
543
Total Assets
145,873.00
111,999.00
69,521.00
38,090.00
39,513.00
124,920
ST Debt & Current Portion LT Debt
853.00
-
33,743.00
19,403.00
5,085.00
Accounts Payable
1,296.00
405.00
939.00
837.00
747.00
Other Current Liabilities
8,830.00
2,509.00
3,074.00
1,725.00
2,907.00
Total Current Liabilities
10,979.00
2,914.00
37,756.00
21,965.00
8,739.00
Long-Term Debt
283.00
-
-
-
-
Other Liabilities
-
-
340.00
54.00
-
Total Liabilities
11,262.00
2,914.00
38,096.00
22,019.00
8,739.00
Common Equity (Total)
134,611.00
109,085.00
31,425.00
16,071.00
30,774.00
Total Shareholders' Equity
134,611.00
109,085.00
31,425.00
16,071.00
30,774.00
Total Equity
134,611.00
109,085.00
31,425.00
16,071.00
30,774.00
Liabilities & Shareholders' Equity
145,873.00
111,999.00
69,521.00
38,090.00
39,513.00

About Catalyst Biosciences

View Profile
Address
611 Gateway Boulevard
South San Francisco California 94080
United States
Employees -
Website http://www.catalystbiosciences.com
Updated 07/08/2019
Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel medicines to address hemophilia condition. Its product pipeline includes FVIIa for the treatment of hemophilia A or B with inhibitors, FIX for hemophilia B treatment, and FXa, which is a universal pro-coagulant. It also develops Anti-C3 CB 2782 for dry age-related macular degeneration.